{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Prostate+Adenocarcinoma+AJCC+v7&page=2",
    "query": {
      "condition": "Stage IV Prostate Adenocarcinoma AJCC v7",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Prostate+Adenocarcinoma+AJCC+v7&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:24:10.640Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03456843",
      "title": "Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Antiandrogen Therapy",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 190,
      "start_date": "2018-03-20",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03456843"
    },
    {
      "nct_id": "NCT03419234",
      "title": "Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma in the Soft Tissue",
        "Prostate Carcinoma Metastatic in the Bone",
        "Stage IV Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Androgen deprivation therapy",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 223,
      "start_date": "2018-04-26",
      "completion_date": "2026-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 665,
      "location_summary": "Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03419234"
    },
    {
      "nct_id": "NCT02601014",
      "title": "Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2016-03-15",
      "completion_date": "2021-10-06",
      "has_results": true,
      "last_update_posted_date": "2022-02-03",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601014"
    },
    {
      "nct_id": "NCT05334069",
      "title": "Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Ann Arbor Stage I Lymphoma",
        "Ann Arbor Stage II Lymphoma",
        "Ann Arbor Stage III Lymphoma",
        "Ann Arbor Stage IV Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myeloid Leukemia",
        "Gastroesophageal Junction Adenocarcinoma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Invasive Breast Carcinoma",
        "Kidney Carcinoma",
        "Malignant Hepatobiliary Neoplasm",
        "Malignant Solid Neoplasm",
        "Melanoma",
        "Muscle-Invasive Bladder Carcinoma",
        "RISS Stage I Plasma Cell Myeloma",
        "RISS Stage II Plasma Cell Myeloma",
        "RISS Stage III Plasma Cell Myeloma",
        "Sarcoma",
        "Stage I Bladder Cancer AJCC v6 and v7",
        "Stage I Breast Cancer AJCC v7",
        "Stage I Colorectal Cancer AJCC v6 and v7",
        "Stage I Esophageal Cancer AJCC V7",
        "Stage I Gastric Cancer AJCC V7",
        "Stage I Lung Cancer AJCC v7",
        "Stage I Ovarian Cancer AJCC v6 and v7",
        "Stage I Pancreatic Cancer AJCC v6 and v7",
        "Stage I Prostate Cancer AJCC v7",
        "Stage I Uterine Corpus Cancer AJCC v7",
        "Stage II Bladder Cancer AJCC v6 and v7",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage II Colorectal Cancer AJCC v7",
        "Stage II Esophageal Cancer AJCC v7",
        "Stage II Gastric Cancer AJCC v7",
        "Stage II Lung Cancer AJCC v7",
        "Stage II Ovarian Cancer AJCC v6 and v7",
        "Stage II Pancreatic Cancer AJCC v6 and v7",
        "Stage II Prostate Cancer AJCC v7",
        "Stage II Uterine Corpus Cancer AJCC v7",
        "Stage III Bladder Cancer AJCC v6 and v7",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Esophageal Cancer AJCC v7",
        "Stage III Gastric Cancer AJCC v7",
        "Stage III Lung Cancer AJCC v7",
        "Stage III Ovarian Cancer AJCC v6 and v7",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage III Prostate Cancer AJCC v7",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IV Bladder Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IV Esophageal Cancer AJCC v7",
        "Stage IV Gastric Cancer AJCC v7",
        "Stage IV Lung Cancer AJCC v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IV Prostate Cancer AJCC v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2022-08-18",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 746,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 501 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05334069"
    },
    {
      "nct_id": "NCT01503229",
      "title": "Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-Resistant Prostate Cancer",
        "Metastatic Prostate Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2012-12",
      "completion_date": "2020-03-12",
      "has_results": true,
      "last_update_posted_date": "2021-05-14",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01503229"
    },
    {
      "nct_id": "NCT02893917",
      "title": "Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation",
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation",
        "Metastatic Prostate Carcinoma",
        "Prostate Adenocarcinoma With Neuroendocrine Differentiation",
        "Stage IV Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cediranib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2017-08-11",
      "completion_date": "2026-06-18",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 16,
      "location_summary": "La Jolla, California • Sacramento, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02893917"
    },
    {
      "nct_id": "NCT02849990",
      "title": "A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Prostate Adenocarcinoma AJCC v7",
        "Stage III Prostate Cancer AJCC v7",
        "Stage IV Prostate Adenocarcinoma AJCC v7",
        "Stage IV Prostate Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        },
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2017-03-09",
      "completion_date": "2020-12-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-13",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02849990"
    },
    {
      "nct_id": "NCT03361735",
      "title": "Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Radium Ra 223 Dichloride",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2018-08-29",
      "completion_date": "2027-01-06",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03361735"
    },
    {
      "nct_id": "NCT03076203",
      "title": "Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Carcinoma Metastatic to the Bone",
        "Stage IV Prostate Adenocarcinoma",
        "Hormone-refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Radium Ra 223 Dichloride",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2017-09-22",
      "completion_date": "2022-11-07",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • New Orleans, Louisiana + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03076203"
    },
    {
      "nct_id": "NCT03406858",
      "title": "Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "PSA Progression",
        "Stage IV Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "HER2Bi-Armed Activated T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2018-06-07",
      "completion_date": "2022-11-07",
      "has_results": true,
      "last_update_posted_date": "2023-05-03",
      "last_synced_at": "2026-05-21T23:24:10.640Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03406858"
    }
  ]
}